NCT01684475Unknown1 期
A STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASE
Alexandra Marine and General Hospital1 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2012年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Reduced signs and symptoms of Parkinson's disease
研究概览
简要总结
The purpose of this study is to assess the ability of CJH1 to increase the sensitivity of dopamine receptors and thereby reduce symptoms of Parkinson's Disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient's with Parkinson's disease
排除标准
- •Contraindications to study medication
研究组 & 干预措施
Treatment with CJH1
Experimental
干预措施: CJH1 (CLR4001) (Drug)
结局指标
主要结局
Reduced signs and symptoms of Parkinson's disease
时间窗: 8 weeks
Reduced signs and symptoms of Parkinson's disease
次要结局
未报告次要终点
研究者
Craig Hudson MD
Psychiatrist
Alexandra Marine and General Hospital
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacodynamic Properties of CJ-12420 on Evening DosingHealthyNCT03043521HK inno.N Corporation24
已完成
1 期
A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and PlasmaHealthyNCT02933762Janssen Research & Development, LLC25
招募中
1 期
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple MyelomaMultiple MyelomaNCT06768489Janssen Research & Development, LLC240
Unknown
2 期
Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality DisorderSchizotypal Personality DisorderCognitive ImpairmentsNCT01466205Larry J. Siever20
已完成
3 期
JT001 (VV116) for the Treatment of COVID-19Mild to Moderate COVID-19NCT05582629Shanghai Vinnerna Biosciences Co., Ltd.1,369